文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

急性低氧性呼吸衰竭与ARDS患者应用Sigh:PROTECTION探索性随机临床试验

Sigh in Patients With Acute Hypoxemic Respiratory Failure and ARDS: The PROTECTION Pilot Randomized Clinical Trial.
PubMed 文献 · Chest · 2020-11-13
一句话结论在急性低氧性呼吸衰竭或ARDS接受PSV的插管患者中,加用Sigh(每分鐘一次气道压升至30 cm H2O持续3 s)可行且不增加风险。

BACKGROUND: Sigh is a cyclic brief recruitment maneuver: previous physiologic studies showed that its use could be an interesting addition to pressure support ventilation to improve lung elastance, decrease regional heterogeneity, and increase release of surfactant.…

要点

  • 随机化后前7天Sigh组氧合改善,潮气量、呼吸频率和校正每分鐘通气量均低于无Sigh组。
  • Sigh实施方案:气道压升至30 cm H2O持续3 s,每分鐘一次,用于接受PSV的急性低氧性呼吸衰竭或ARDS成人插管患者。

适用人群与场景

  • 成人插管患者,因急性低氧性呼吸衰竭或ARDS接受压力支持通气(PSV)者。
  • 排除人群及具体纳入标准原文未提及。

诊断标准与关键阈值

  • 主要终点可行性以辅助通气失败比例的非劣效性评估,容差为5%。

处置流程与药物剂量

  • Sigh组在PSV基础上加用Sigh:气道压升至30 cm H2O,持续3 s,每分鐘一次。
  • 干预持续至第28天或死亡或成功自主呼吸试验。
  • 无Sigh组仅接受PSV治疗。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 随机化后前7天Sigh组氧合改善,潮气量、呼吸频率和校正每分鐘通气量低于无Sigh组。

证据类型、等级与局限

  • 证据类型:多中心非劣效性随机临床试验(探索性)。

对床旁实践的改变

  • 对接受PSV的急性低氧性呼吸衰竭或ARDS成人插管患者,可考虑加用Sigh(气道压30 cm H2O持续3 s、每分鐘一次)作为可行干预,不增加不良事件风险。
  • Sigh可能改善氧合并降低潮气量、呼吸频率和校正每分鐘通气量,但死亡率与无呼吸机天数无显著差异。
  • 适用人群为接受PSV的急性低氧性呼吸衰竭或ARDS成人插管患者;排除人群原文未提及。
  • 常见陷阱:原文未提及。

指南或共识出处

  • PROTECTION Pilot Randomized Clinical Trial(Chest),试验注册号NCT03201263。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Sigh is a cyclic brief recruitment maneuver: previous physiologic studies showed that its use could be an interesting addition to pressure support ventilation to improve lung elastance, decrease regional heterogeneity, and increase release of surfactant.

RESEARCH QUESTION: Is the clinical application of sigh during pressure support ventilation (PSV) feasible?

STUDY DESIGN AND METHODS: We conducted a multicenter noninferiority randomized clinical trial on adult intubated patients with acute hypoxemic respiratory failure or ARDS undergoing PSV. Patients were randomized to the no-sigh group and treated by PSV alone, or to the sigh group, treated by PSV plus sigh (increase in airway pressure to 30 cm H2O for 3 s once per minute) until day 28 or death or successful spontaneous breathing trial. The primary end point of the study was feasibility, assessed as noninferiority (5% tolerance) in the proportion of patients failing assisted ventilation. Secondary outcomes included safety, physiologic parameters in the first week from randomization, 28-day mortality, and ventilator-free days.

RESULTS: Two-hundred and fifty-eight patients (31% women; median age, 65 [54-75] years) were enrolled. In the sigh group, 23% of patients failed to remain on assisted ventilation vs 30% in the no-sigh group (absolute difference, -7%; 95% CI, -18% to 4%; P = .015 for noninferiority). Adverse events occurred in 12% vs 13% in the sigh vs no-sigh group (P = .852). Oxygenation was improved whereas tidal volume, respiratory rate, and corrected minute ventilation were lower over the first 7 days from randomization in the sigh vs no-sigh group. There was no significant difference in terms of mortality (16% vs 21%; P = .337) and ventilator-free days (22 [7-26] vs 22 [3-25] days; P = .300) for the sigh vs no-sigh group.

INTERPRETATION: Among hypoxemic intubated ICU patients, application of sigh was feasible and without increased risk.

TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT03201263; URL: www.clinicaltrials.gov.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Mauri T, Foti G, Fornari C, et al. Sigh in Patients With Acute Hypoxemic Respiratory Failure and ARDS: The PROTECTION Pilot Randomized Clinical Trial. Chest. 2020. PMID: 33197403. doi:10.1016/j.chest.2020.10.079

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。